CREDENCE Trial Visual Abstract
In CREDENCE trial, the authors objective was to assess the effect of canagliflozin on renal outcomes in patients with type 2 DM and CKD. 4,401 patients with CKD and DM2 were enrolled to be treated with either 100 mg canagliflozin daily or matched placebo. The primary outcome of ESRD, worsening CKD or CV death was significantly lower in patients on canagliflozin (P=0.0001). The authors concluded that canagliflozin can significantly protect kidney in patients with diabetes. Take a look and share the visual abstract for quick learning.
Want to read more posts?